Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable.
The question about Historical amylin analogues that I actually want answered is the second one below. The first is context and I have kept it short.
Both are stated with units, and I have said what I already checked so that nobody repeats it.
What would change my mind on Historical amylin analogues is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.
I read the opening post twice before replying, because I had assumed the opposite.
Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.
Post #3 answers the question as asked. The question underneath it is different.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
That is my reading. Someone else read the same page differently and was reasonable.
Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.
It reads as pedantry until the day it does not.
On analysis: an amylin analogue and its aggregates are not equally detectable by a standard reversed-phase method, because a large aggregate may not elute at all. Area percent cannot see what stays on the column.
Narrowing post #7, because the general version has more than one answer.
For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.
Post #7 put the caveat in the right place and I want to underline it.
Anyone submitting this for independent testing should say in the submission that it is an amylin analogue rather than an incretin. Method selection differs and a default incretin gradient is not necessarily the right one.
This is where my knowledge stops and I would rather mark the edge than blur it.
Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.
Anyone with a larger sample, please post it.
Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.
Worth distinguishing the combination product from the two components bought separately and mixed. Those are different pharmaceutical objects and nothing published about the first applies to the second.
What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.
Filing this under things that are true until someone shows me otherwise.
Post #10 and I disagree about the size of the effect, not about the direction.
Practical experience of Historical amylin analogues, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.
I would treat that as a working assumption and revisit it.
That is consistent with mine, for whatever one more account is worth.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
Noting that the question and the thing people usually mean by it are different.
Answering the question post #19 raises rather than the one it answers.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.
Written quickly, so the reasoning may be tighter than the wording.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: What is genuinely unknown about long-term amylin agonism
What is genuinely unknown about long-term amylin agonism I have a specific reason for asking rather than idle curiosity, and the context is below. Putting the numbers in the first post, because a question…
|
2 | 25k | 11mo | |
|
Second pass at: Cagrilintide molecular characteristics and analytical considerations
On the subject in the title: Second pass at: Cagrilintide molecular characteristics and analytical considerations Working notes rather than a conclusion. Something about Cagrilintide molecular characteristics…
|
4 | 5k | 21d | |
|
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1
On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. Trying to work out what would count as evidence on Amylin analogue…
|
+27 | 31 | 671 | 12mo |
|
Why cagrilintide alone is discussed so much less than in combination — does this still hold?
Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Cagrilintide alone:…
|
+27 | 31 | 1.2k | 22h |
|
Amylin analogue mechanism: satiety signalling separate from GLP-1
Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on amylin analogue…
|
+128 | 142 | 38k | 13mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Criticising the method without criticising the authors
Criticising the method without criticising the authors Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about criticising the method without criticising in a…
|
+55 | 61 | 60k | 15mo |
|
Triple agonism: additive, synergistic, or neither?
The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Asking about triple agonism on behalf of the question I keep…
|
+71 | 80 | 38k | 11mo |
|
[2026 update] Journal club: is percentage weight change the right endpoint?
Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about what the numbers mean rather than what…
|
+105 | 118 | 18k | 11mo |
|
The C-cell question: rodent findings and their human context
Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. The question about c-cell question that I actually want…
|
+41 | 45 | 24k | 12mo |
|
Adjudicated events and why the definition matters — the long version
Adjudicated events and why the definition matters — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Adjudicated events, deliberately…
|
+125 | 146 | 13k | 15mo |